Yang et al. developed armed third-generation PD-L1-targeted ACR/CAR T cells utilizing a PD-1/PD-L1 immune checkpoint axis. Both engineered CAR T cells significantly improved tumor control and survival in models of PD-L1-expressed pancreatic cancers.
|Number of pages||15|
|Journal||Molecular Therapy - Oncolytics|
|Publication status||Published - Jun 26 2020|
ASJC Scopus subject areas
- Molecular Medicine
- Cancer Research
- Pharmacology (medical)